243 related articles for article (PubMed ID: 9715260)
1. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
2. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
3. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
4. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells.
Lanza F; Castoldi GL; Castagnari B; Todd RF; Moretti S; Spisani S; Latorraca A; Focarile E; Roberti MG; Traniello S
Br J Haematol; 1998 Oct; 103(1):110-23. PubMed ID: 9792297
[TBL] [Abstract][Full Text] [Related]
5. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
[TBL] [Abstract][Full Text] [Related]
6. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Sloand EM; Pfannes L; Scheinberg P; More K; Wu CO; Horne M; Young NS
Exp Hematol; 2008 Dec; 36(12):1616-24. PubMed ID: 18954937
[TBL] [Abstract][Full Text] [Related]
7. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Plesner T; Ploug M; Ellis V; Rønne E; Høyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Danø K; Hansen NE
Blood; 1994 Feb; 83(3):808-15. PubMed ID: 8298141
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
9. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
12. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).
Pliyev BK
Mol Cell Biochem; 2009 Jan; 321(1-2):111-22. PubMed ID: 18830568
[TBL] [Abstract][Full Text] [Related]
13. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
Behrendt N; Danø K
FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
[TBL] [Abstract][Full Text] [Related]
14. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
16. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
17. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
Sidenius N; Andolfo A; Fesce R; Blasi F
J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
[TBL] [Abstract][Full Text] [Related]
18. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
19. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction.
Høyer-Hansen G; Behrendt N; Ploug M; Danø K; Preissner KT
FEBS Lett; 1997 Dec; 420(1):79-85. PubMed ID: 9450554
[TBL] [Abstract][Full Text] [Related]
20. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-uPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics.
Guthaus E; Bürgle M; Schmiedeberg N; Hocke S; Eickler A; Kramer MD; Sweep CG; Magdolen V; Kessler H; Schmitt M
Biol Chem; 2002 Jan; 383(1):207-16. PubMed ID: 11930939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
